In Reply First, the purpose of our study¹ was explicitly described as assessing the implications of lipoprotein(a) screening in the context of primary prevention for atherosclerotic cardiovascular disease, with a particular emphasis on individuals not already being treated with statin therapy. Elevated lipoprotein(a) levels for primary prevention includes lifestyle counseling and statin therapy; thus, including individuals already treated with statin therapy may not be informative.^2,3 However, we do agree that, as described in the Limitations section,¹ the UK Biobank cohort has a healthy volunteer bias and is predominately composed of individuals of European ancestry, which may limit the generalizability of some of our results.

在第一答复中，我们研究¹的目的被明确描述为评估脂蛋白（a）筛查在动脉粥样硬化性心血管疾病一级预防中的影响，特别强调尚未接受他汀类药物治疗的个体。用于一级预防的升高的脂蛋白（a）水平包括生活方式咨询和他汀类药物治疗；因此，包括已经接受他汀类药物治疗的个体可能无法提供信息。^{2 ,3}但是，我们确实同意，如限制部分所述，¹英国生物银行队列具有健康的志愿者偏见，并且主要由欧洲血统的个体组成，这可能会限制我们某些结果的普遍性。